AstraZeneca Pharma India (506820) Q4 24/25 earnings summary

Executive summary

• Achieved 32% year-over-year revenue growth, reaching INR 17,162.9 million for FY 2024-25, with strong performance across all therapeutic areas.

• Core EPS for the year was INR 46.30, reflecting robust profitability.

• Board recommended a final dividend of INR 32 per equity share, totaling INR 800 million, subject to shareholder approval.

• Statutory auditor's report issued an unmodified opinion on the financial statements.

Financial highlights

• Revenue from operations for FY 2024-25 was INR 17,162.9 million, up from INR 12,955.3 million in FY 2023-24.

• Profit before exceptional items and tax was INR 2,531.5 million, compared to INR 2,031.1 million last year.

• Profit after tax and exceptional items stood at INR 1,157.4 million, down from INR 1,615.1 million in the previous year due to higher exceptional costs.

• Q4 FY 2024-25 revenue was INR 4,804.8 million, up from INR 3,832.0 million in Q4 FY 2023-24.

Outlook and guidance

• Management highlighted continued momentum into 2025 and beyond, driven by innovative medicine launches and a focus on science-led growth.